Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drug Therapy01:28

Drug Therapy

103
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
103
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

761
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
761
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plant-based calcitriol reduced the requirements of calcium and available phosphorus in broiler chicken diet.

British poultry science·2025
Same author

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.

Blood reviews·2025
Same author

6-Bromo-9,9-diethyl-<i>N</i>,<i>N</i>-di-phenyl-fluoren-2-amine.

IUCrData·2025
Same author

(1<i>H</i>-Benzo-diazol-2-ylmeth-yl)di-ethyl-amine.

IUCrData·2024
Same author

Improved tomato leaf disease classification through adaptive ensemble models with exponential moving average fusion and enhanced weighted gradient optimization.

Frontiers in plant science·2024
Same author

Supplemental phosphorus can be completely replaced with microbial phytase in White Leghorn layer diets.

British poultry science·2024

Related Experiment Video

Updated: Sep 14, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?

R Vijjhalwar1, A Kannan2, C Fuentes-Lacouture3

  • 1University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|July 21, 2025
PubMed
Summary

Managing relapsed multiple myeloma (MM) involves deciding between switching drug classes or re-treating with the same agents. Personalized treatment strategies are crucial for optimizing outcomes in relapsed MM patients.

Keywords:
BCMA Targeted TherapiesBiochemical RelapseRelapsed MyelomaRetreatment

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Experiment Videos

Last Updated: Sep 14, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a significant hematological malignancy with no current cure.
  • Relapsed MM presents complex treatment challenges due to disease evolution and drug resistance.

Purpose of the Study:

  • To explore the decision-making process for treating relapsed multiple myeloma.
  • To evaluate strategies for drug class switching versus re-treatment in relapsed MM.

Main Methods:

  • Review of clinical decision-making in relapsed multiple myeloma.
  • Discussion of a clinical vignette involving a patient with biochemical relapse after lenalidomide maintenance.

Main Results:

  • The choice between switching drug classes or re-treatment depends on patient-specific factors and prior treatment response.
  • New drug classes (XPO1 inhibitors, BCMA-targeted, GPRC5d-targeted agents) add complexity to treatment decisions.

Conclusions:

  • Personalized treatment approaches are essential for optimizing outcomes in relapsed MM.
  • Balancing therapeutic efficacy with patient tolerability and quality of life is key in managing relapsed MM.